On the 9th of February, Orbimed Advisors added 475 thousand Terns Pharmaceuticals, Inc. (TERN) shares for $8.1 million at an average price of $17.00 per share.
Shares of Terns Pharmaceuticals, Inc. are down -0.96% since the transaction.
Orbimed Advisors’s holding in Terns Pharmaceuticals, Inc. increased to about 2.3 million shares with the purchase.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.